NS-050/NCNP-03

Phase 2Small molecule

NS Pharma

NS-050/NCNP-03 is one of 4 small molecule programs targeting DMD. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DMDRecruiting

DMDPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in DMD

#DrugCompanyPhaseTrials

AOC 1020

AAvidity Biosciences, Inc.

Phase 2

1 2

NS-089/NCNP-02

NS Pharma

Phase 2

2 3

NS-050/NCNP-03

NS Pharma

Phase 2

1 4

Aoc 1044

AAvidity Biosciences, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

DMD

NCT06053814

Clinical

Trials by Indication[1]

DMD1 trial

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Recruiting· NS Pharma logo

NS Pharma·Phase 1/2·NCT06053814·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NS-050/NCNP-03. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NS-050/NCNP-03 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NS-050/NCNP-03. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NS Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NS Pharma

NS-050/NCNP-03

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

DMD1 trial

References

Drug Info

Quick Facts

Related News